BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23612467)

  • 1. Screening for prostate cancer in New Zealand general practice.
    Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
    J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
    Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
    J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA screening in New Zealand: total population results and general practitioners' current attitudes and practices.
    van Rij S; Dowell T; Nacey J
    N Z Med J; 2013 Aug; 126(1381):27-36. PubMed ID: 24150262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA testing in general practice.
    Hodgson F; Obertová Z; Brown C; Lawrenson R
    J Prim Health Care; 2012 Sep; 4(3):199-204. PubMed ID: 22946067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of prostate cancer screening in a UK region.
    Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
    BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
    Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
    Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: what do general practitioners think?
    Morris J; McNoe B
    N Z Med J; 1997 May; 110(1044):178-82. PubMed ID: 9201202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
    Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
    BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline prostate-specific antigen testing at a young age.
    Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
    Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer of the prostate. Should men be screened, how to screen, when to screen?].
    Abbou CC; Haillot O; Ravery V
    Ann Urol (Paris); 1996; 30(6-7):283-6; discussion 286-93. PubMed ID: 9092382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
    Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
    BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.
    McDavid K; Melnik TA; Derderian H
    Prev Med; 2000 Sep; 31(3):195-202. PubMed ID: 10964632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
    Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
    Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.